Source comparison
Melanotan-1 Pharmacokinetics: Compound Comparison
Time to Peak (Tmax) 30 minutes (subcutaneous) 60–90 minutes 5–10 minutes (IV) Melanotan-1's rapid Tmax allows precise experimental timing without the prolonged lead-in required for MT-2 Plasma Half-Life (t½) 30–40 minutes 1–2 hours 1–3 minutes The short half-l
This comparison does not assign a generated winner or score.
- Time to Peak (Tmax)
- 30 minutes (subcutaneous)
- 60–90 minutes
- 5–10 minutes (IV)
- Melanotan-1's rapid Tmax allows precise experimental timing without the prolonged lead-in required for MT-2
- Plasma Half-Life (t½)
- 30–40 minutes
- 1–2 hours
- 1–3 minutes
- The short half-life of melanotan-1 prevents receptor desensitisation while clearing before off-target effects emerge
- Bioavailability (SC)
- 94–98%
- 85–90%
- Not applicable (rapidly degraded)
- Near-complete bioavailability makes subcutaneous dosing as predictable as IV administration
- Primary Clearance Route
- Renal filtration
- Enzymatic degradation (plasma peptidases)
- Renal clearance produces consistent elimination kinetics without inter-individual variability from hepatic metabolism
- Receptor Selectivity
- MC1R > MC3R, MC4R, MC5R
- Non-selective (all MCRs)
- Broad MCR activation
- Melanotan-1's MC1R selectivity reduces confounding effects from appetite, cardiovascular, or sebaceous pathways
- Volume of Distribution (Vd)
- 0.25–0.35 L/kg
- 0.5–0.7 L/kg
- 0.1–0.15 L/kg
- Lower Vd indicates extracellular distribution without significant tissue binding or sequestration